Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GIS02 is a preclinical-stage cosmetic candidate developed by Exostemtech, utilizing exosomes derived from ginseng (Panax ginseng). These plant-derived extracellular vesicles, often referred to as exosome-like nanoparticles (ELNs), serve as a specialized delivery system for bioactive ginseng components, including ginsenosides, proteins, and RNAs. The product is designed for topical cosmetic applications, where it aims to promote skin regeneration, enhance collagen synthesis, and provide anti-inflammatory and anti-aging effects. By leveraging the natural encapsulation properties of exosomes, GIS02 is intended to offer improved stability and deeper skin penetration of active ingredients compared to traditional ginseng extracts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GIS02.